Cargando…

Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015

The U.S. Food and Drug Administration (FDA) approves new drugs every year. Drug targets are some of the most important interactive molecules for drugs, as they have a significant impact on the therapeutic effects of drugs. In this work, we thoroughly analyzed the data of small molecule drugs approve...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Hui-Heng, Zhang, Le-Le, Yan, Ru, Lu, Jin-Jian, Hu, Yuanjia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612934/
https://www.ncbi.nlm.nih.gov/pubmed/28947756
http://dx.doi.org/10.1038/s41598-017-12061-8
_version_ 1783266144230047744
author Lin, Hui-Heng
Zhang, Le-Le
Yan, Ru
Lu, Jin-Jian
Hu, Yuanjia
author_facet Lin, Hui-Heng
Zhang, Le-Le
Yan, Ru
Lu, Jin-Jian
Hu, Yuanjia
author_sort Lin, Hui-Heng
collection PubMed
description The U.S. Food and Drug Administration (FDA) approves new drugs every year. Drug targets are some of the most important interactive molecules for drugs, as they have a significant impact on the therapeutic effects of drugs. In this work, we thoroughly analyzed the data of small molecule drugs approved by the U.S. FDA between 2000 and 2015. Specifically, we focused on seven classes of new molecular entity (NME) classified by the anatomic therapeutic chemical (ATC) classification system. They were NMEs and their corresponding targets for the cardiovascular system, respiratory system, nerve system, general anti-infective systemic, genito-urinary system and sex hormones, alimentary tract and metabolisms, and antineoplastic and immunomodulating agents. To study the drug–target interaction on the systems level, we employed network topological analysis and multipartite network projections. As a result, the drug–target relations of different kinds of drugs were comprehensively characterized and global pictures of drug–target, drug–drug, and target–target interactions were visualized and analyzed from the perspective of network models.
format Online
Article
Text
id pubmed-5612934
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-56129342017-10-11 Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015 Lin, Hui-Heng Zhang, Le-Le Yan, Ru Lu, Jin-Jian Hu, Yuanjia Sci Rep Article The U.S. Food and Drug Administration (FDA) approves new drugs every year. Drug targets are some of the most important interactive molecules for drugs, as they have a significant impact on the therapeutic effects of drugs. In this work, we thoroughly analyzed the data of small molecule drugs approved by the U.S. FDA between 2000 and 2015. Specifically, we focused on seven classes of new molecular entity (NME) classified by the anatomic therapeutic chemical (ATC) classification system. They were NMEs and their corresponding targets for the cardiovascular system, respiratory system, nerve system, general anti-infective systemic, genito-urinary system and sex hormones, alimentary tract and metabolisms, and antineoplastic and immunomodulating agents. To study the drug–target interaction on the systems level, we employed network topological analysis and multipartite network projections. As a result, the drug–target relations of different kinds of drugs were comprehensively characterized and global pictures of drug–target, drug–drug, and target–target interactions were visualized and analyzed from the perspective of network models. Nature Publishing Group UK 2017-09-25 /pmc/articles/PMC5612934/ /pubmed/28947756 http://dx.doi.org/10.1038/s41598-017-12061-8 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lin, Hui-Heng
Zhang, Le-Le
Yan, Ru
Lu, Jin-Jian
Hu, Yuanjia
Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
title Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
title_full Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
title_fullStr Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
title_full_unstemmed Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
title_short Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
title_sort network analysis of drug–target interactions: a study on fda-approved new molecular entities between 2000 to 2015
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612934/
https://www.ncbi.nlm.nih.gov/pubmed/28947756
http://dx.doi.org/10.1038/s41598-017-12061-8
work_keys_str_mv AT linhuiheng networkanalysisofdrugtargetinteractionsastudyonfdaapprovednewmolecularentitiesbetween2000to2015
AT zhanglele networkanalysisofdrugtargetinteractionsastudyonfdaapprovednewmolecularentitiesbetween2000to2015
AT yanru networkanalysisofdrugtargetinteractionsastudyonfdaapprovednewmolecularentitiesbetween2000to2015
AT lujinjian networkanalysisofdrugtargetinteractionsastudyonfdaapprovednewmolecularentitiesbetween2000to2015
AT huyuanjia networkanalysisofdrugtargetinteractionsastudyonfdaapprovednewmolecularentitiesbetween2000to2015